ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,071.63
0.02%
US Tech 100
16,926.80
-0.78%
Dow Jones
38,460.92
-0.11%
Brent Oil
87.135
-0.10%
Bitcoin
63,949.92
-0.52%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Sonnet BioTherapeutics Holdings Inc (SONN) Quote

Sonnet BioTherapeutics Holdings Inc

Sonnet BioTherapeutics Holdings Inc (SONN)

NASDAQ
1.845
0.07
(3.65%)
Closed April 24 4:00PM
Delayed by 15 minutes
1.845
0.00
( 0.00% )
Pre Market: 4:00AM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
1.845
Bid
1.79
Ask
1.90
Volume
-
0.00 Day's Range 0.00
1.08 52 Week Range 26.40
Market Cap
5.648M
Previous Close
1.845
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
109,387
Shares Outstanding
3,069,516
Dividend Yield
-
PE Ratio
-0.30
Earnings Per Share (EPS)
-6.14
Revenue
148k
Net Profit
-18.83M

About Sonnet BioTherapeutics Holdings Inc

Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and... Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others. Show more

Sector
Pharmaceutical Preparations
Industry
Management Consulting Svcs
Website
www.sonnetbio.com
Headquarters
Wilmington, Delaware, USA
Founded
2020
Sonnet BioTherapeutics Holdings Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SONN. The last closing price for Sonnet BioTherapeutics was $1.85. Over the last year, Sonnet BioTherapeutics shares have traded in a share price range of $ 1.08 to $ 26.40.

Sonnet BioTherapeutics currently has 3,069,516 shares outstanding. The market capitalization of Sonnet BioTherapeutics is $5.65 million. Sonnet BioTherapeutics has a price to earnings ratio (PE ratio) of -0.30.

SONN Latest News

More News

Form 8-K - Current report

March 11 2024
Edgar (US Regulatory)

Form 8-K - Current report

February 14 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

February 14 2024
Edgar (US Regulatory)

Form 8-K - Current report

February 01 2024
Edgar (US Regulatory)

Form 8-K - Current report

January 29 2024
Edgar (US Regulatory)

Form EFFECT - Notice of Effectiveness

January 05 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

January 02 2024
Edgar (US Regulatory)

Form 8-K - Current report

December 27 2023
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.1357.894736842111.711.891.66163681.77502315CS
4-0.125-6.345177664971.972.11.65245791.87772347CS
120.35523.82550335571.492.33991.311093871.9784297CS
260.67557.69230769231.172.33991.08887721.74710925CS
52-4.095-68.93939393945.9426.41.08127943710.1496358CS
156-654.195-99.7187671483656.04840.841.082930374151.46150318CS
260-1913.915-99.90369357331915.764989.61.082613203329.7186969CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ILAGIntelligent Living Application Group Inc
$ 0.8352
(54.67%)
2.69M
AIREreAlpha Tech Corporation
$ 1.61
(38.79%)
1.35M
CDTXCidara Therapeutics Inc
$ 16.00
(30.19%)
22.21k
MRINMarin Software Incorporated
$ 2.95
(25.00%)
15
CULLCullman Bancorp Inc
$ 12.49
(20.27%)
21
ZAPPZapp Electric Vehicles Group Ltd
$ 2.67
(-31.71%)
605
CSSEChicken Soup for the Soul Entertainment Inc
$ 0.3119
(-26.66%)
593.3k
FBLGraniteShares ETF Trust GraniteShares
$ 20.00
(-25.29%)
81.33k
BPTSBiophytis SA
$ 8.00
(-17.55%)
837
ADTXAditxt Inc
$ 2.02
(-14.77%)
1
SBFMSunshine Biopharma Inc
$ 1.005
(8.06%)
3.25M
ILAGIntelligent Living Application Group Inc
$ 0.8352
(54.67%)
2.69M
NUWENewellis Inc
$ 0.2903
(15.15%)
1.36M
AIREreAlpha Tech Corporation
$ 1.61
(38.79%)
1.35M
SQQQProShares UltraPro Short QQQ
$ 12.115
(2.58%)
1.21M

SONN Discussion

View Posts
BooDog BooDog 1 week ago
I see 76 followers here. And I have a target price of around 1.50 for support.

GL.

I do own shares and am looking for this to have a good future.
👍️0
maq1214 maq1214 1 month ago
Something must be happening behind closed doors. This stock has been ridiculously quite since the RS. Glad it’s greening again !
👍️0
81vette 81vette 1 month ago
23,198 watchers now,word is spreading like wildfire,somebody with lots of followers must be promoting this
👍️0
81vette 81vette 1 month ago
They are rare,not 1 in a million lotto rare but only a few per year maybe happen,the chart is great,how many bio pharma are bullish for 5 months straight (1 in a million lol) has accumulated also and that is very promising
👍️0
maq1214 maq1214 1 month ago
Do you think we are likely to see a merger/ partnership? I;m really hoping the reverse split last year cost me a lot
👍️0
81vette 81vette 1 month ago
$2.23 is 5 month high,next res. $5 mental,$7.57(sma200),big gaps to fill,mental 10/15/20/25 ect. lots of blue sky past 7.57,any kind of merger/buyout news could send it,thats the hype/hope/pump talk right now
👍️0
81vette 81vette 1 month ago
254k short,could squeeze with ZERO BORROW,73% fee(no rebate),5 months of accumulation= in the know are loading
👍️0
81vette 81vette 1 month ago
5 month uptrend(since r/s)accumulation,zero borrow,moving today on low vol(up13%),clinical trials different stages,float 2.78m,o/s 3m
👍️0
BooDog BooDog 1 month ago
Riding free again.
👍️0
Monksdream Monksdream 2 months ago
SONN under $2
👍️0
crowin crowin 2 months ago
Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Lowers Price Target to $30
👍️0
maq1214 maq1214 2 months ago
This should get exciting soon, crazy volume yesterday !
👍️0
BooDog BooDog 3 months ago
IS it just greed or might this make good for another round trip? We'll see next week.
👍️0
BooDog BooDog 4 months ago
Good move IMO. Surprising actually.

On December 27, 2023, the Compensation Committee (the “Committee”) of the Board of Directors of Sonnet BioTherapeutics Holdings, Inc. (the “Company”) cancelled accrued but unpaid bonuses (the “Cancelled Bonuses”) that had been awarded for fiscal years 2022 and 2023 by the Committee to certain executive officers and employees of the Company. The Cancelled Bonuses total $1,930,773.10 and include (i) $631,768.12 awarded to Pankaj Mohan, Ph.D., the Company’s President and Chief Executive Officer, (ii) $312,741.79 awarded to John Cini, Ph.D, the Company’s Chief Scientific Officer and (iii) $364,504.40 awarded to Jay Cross, the Company’s Chief Financial Officer.

https://ih.advfn.com/stock-market/NASDAQ/sonnet-biotherapeutics-SONN/stock-news/92897290/form-8-k-current-report
👍️0
Monksdream Monksdream 6 months ago
SONN new 52 week low
👍️0
BooDog BooDog 6 months ago
Discount. Maybe I should have added "again". 1.60 offering and this is pushing towards the $. Very small float. Just playing the bounce. IF there is one lol.

https://www.accesswire.com/viewarticle.aspx?id=796208
👍️0
valleybenedetto valleybenedetto 6 months ago
Absolute piece of shit co, shit stock, dilution is endless. CEO should be fired. Sell now
👍️0
Monksdream Monksdream 6 months ago
SONN new 52 week low
👍️0
Monksdream Monksdream 7 months ago
SONN new 52 week low
👍️0
Monksdream Monksdream 7 months ago
SONN new 52 week low
👍️0
Monksdream Monksdream 7 months ago
SONN new 52 week low
👍️0
valleybenedetto valleybenedetto 7 months ago
If they would stop shitting on shareholders, cut costs and actually get something accomplished that would be a start.
👍️0
Monksdream Monksdream 7 months ago
If the stock continues to make new lows on its way to a delisting to Cromwell Coulson’s stock market or a dissolution I will continue to record it
👍️0
valleybenedetto valleybenedetto 7 months ago
You worry about you ok?
👍️0
Monksdream Monksdream 7 months ago
You aren’t getting any money back
Time to move on
👍️0
valleybenedetto valleybenedetto 7 months ago
Not an Urban Myth ..I've already checked. They have current D and O insurance.
👍️0
Monksdream Monksdream 7 months ago
Oh goddamn tell me another urban myth
👍️0
valleybenedetto valleybenedetto 7 months ago
They have D and O insurance. That's where you collect from. That's directors and officers insurance if you didn't know
👍️0
Monksdream Monksdream 7 months ago
You wouldn’t get anything from a class action lawsuit
Anyone connected to professional asset management abandoned this company long ago
👍️0
valleybenedetto valleybenedetto 7 months ago
CEO is awful. Nothing but offerings and RS. No meaningful news in months. Class action suit might be in order here.
👍️0
Monksdream Monksdream 7 months ago
SONN new 52 week low
👍️0
Golden Cross Golden Cross 7 months ago
Might be a short play here now
👍️0
Golden Cross Golden Cross 8 months ago
Very true.....
👍️0
antman antman 8 months ago
...During his testimony, Elon Musk called short selling “a means for, in my opinion, bad people on Wall Street to steal money from small investors.”
👍️0
tw0122 tw0122 8 months ago
Biotech CEOs are mostly Wall Street whores they get compensated to short there own companies as it’s much more lucrative. They take on that toxic financing do reverse splits as part of their regular routine. Take MULN CEO for example he has no scruples or morals nor does he hide his screwing over shareholders.
As far as trading you play the post reverse splits at the right time with the low float and that is where the loot is made.
Wall Street casino.
👍️0
valleybenedetto valleybenedetto 8 months ago
CEO is an incompetent whore. Stock ran to 1.20 . Instead of letting it sit for 10 days and regain compliance he jammed an offering down and screwed everyone.
👍️0
antman antman 8 months ago
I guess the shorts just crush all these companies and force them to do rollbacks
👍️0
Golden Cross Golden Cross 8 months ago
Don't see the vote not passing now
👍️0
Golden Cross Golden Cross 8 months ago
Nothing has gone right since the offering.. Time for a turnaround here... loading up
👍️0
Golden Cross Golden Cross 8 months ago
Yep
👍️0
govprs govprs 8 months ago
Did you see the letter to shareholders?
👍️0
Golden Cross Golden Cross 8 months ago
needs something here
👍️0
TimeFades TimeFades 8 months ago
See if she can start a new uptrend
👍️0
tw0122 tw0122 8 months ago
Nice to see the new Fibonacci targets going the other way now
👍️0
Golden Cross Golden Cross 8 months ago
$SONN Sonnet BioTherapeutics Provides Fiscal Year 2023 Third Quarter Business and Earnings Update
https://www.accesswire.com/773690/Sonnet-BioTherapeutics-Provides-Fiscal-Year-2023-Third-Quarter-Business-and-Earnings-Update
👍️0
limer814 limer814 9 months ago
$SONN Whoever John Markey is ,he knows something we don't. Another 13g filed this am . He is up to 4.1m shares now..I'm still holding pic.twitter.com/AW4hN0Secj— Keith Rah (@keith_rah) August 7, 2023
👍️0
starkd748 starkd748 9 months ago
Around .27 gap fill....Glad I read charts prs and filings about share purchases don't mean squat
👍️0
surf1944 surf1944 9 months ago
https://stockcharts.com/h-sc/ui?s=sonn&p=D&yr=0&mn=6&dy=0&id=p38090673899

https://www.barchart.com/stocks/quotes/sonn/technical-chart?plot=CANDLE&volume=total&data=DO&density=M&pricesOn=1&asPctChange=0&logscale=1&indicators=BBANDS(20,2);SMA(13);PTP(50);ADX(14);SMA(50);SMACD(12,26,9);RSI(14,100);ACCUM;STOSL(14,3)&sym=CNNA&grid=1&height=500&studyheight=100

https://www.barchart.com/stocks/quotes/sonn/opinion
👍️0
Golden Cross Golden Cross 9 months ago
Sonnet BioTherapeutics to Present at the 2023 BTIG Virtual Biotechnology Conference
https://www.accesswire.com/771212/Sonnet-BioTherapeutics-to-Present-at-the-2023-BTIG-Virtual-Biotechnology-Conference
👍️0
Golden Cross Golden Cross 9 months ago
That didn't look good
👍️0

Your Recent History

NASDAQ
SONN
Sonnet BioTherapeutics
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved